Schering gets FDA approval for Yaz

Schering AG has announced that the Food and Drug Administration (FDA) in the US has granted the company approval for its new oral contraceptive, Yaz.

Yaz is a low dose, monophasic oral contraceptive, which works on a regimen of 24 days of active hormone pills and four days of placebo, as opposed to the traditional regimen of 21 days of active hormone pills and seven days of placebo.

“The Yaz approval is an important milestone for Schering. This significantly adds to the blockbuster potential of our Yasmin product family,” said Dr. Hubertus Erlen, chairman of the executive board of Schering AG.

“Yaz joins the most innovative oral contraceptive portfolio worldwide, and will certainly contribute to our near and long-term success.”

This first approval by the FDA is not the end of the pursuit for Schering and Yaz, however. The company has said that it is still searching for FDA approval for the use of Yaz as a treatment for the emotional and physical symptoms of premenstrual dysphoric disorder.

The Schering contraceptive Yasmin is, the company says, the number one brand birth control worldwide.

© Adfero Ltd